Depressive Disorder Clinical Trial
Official title:
Research on Voice Intelligent Monitoring Technology for Early Warning of Recurrence of Depression Disorder
This study aims to collect the voice output of depression patients and healthy subjects, extract the acoustic and semantic parameters, compare the similarities and differences between the depression group and the healthy control group horizontally, and track the depression patients' changes in the rehabilitation stage to construct a voice-based early warning model of depression recurrence. At the same time, the use of EEG technology, nuclear magnetic resonance and near-infrared brain imaging technology to record and analyze the neural activity characteristics behind the voice variation of depression patients, and build a neural mechanism model. And construct the facial recognition function through the convolutional neural network, extract the facial parameters to enrich the intelligent monitoring and early warning technology. 1. Collect linguistic data of depression patients and healthy people collected in the laboratory, as well as data related to changes in the condition of depression patients in daily life and home care after treatment, and construct comparative data and dynamic observations Large database to analyze its voice mutation characteristics; 2. Using EEG technology, nuclear magnetic resonance, and near-infrared brain imaging to record and analyze the neural activity characteristics behind the voice variation of depression patients, and build a neural mechanism model. 3. Use the convolutional neural network to realize the facial recognition function, and extract the facial parameters to enrich the monitoring indicators. 4. Based on the dynamic observation big data of depression speech mutation, construct the speech feature parameter vector of depression recurrence, and use adaptive personalized intelligent learning algorithm to develop intelligent monitoring and early warning technology. 5. Establish monitoring and diagnostic indicators for recurrence early warning, verify the application of the above-mentioned intelligent monitoring and early warning technology in rehabilitation guidance, and make a comprehensive assessment.
Status | Recruiting |
Enrollment | 240 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Patients with depression in the consolidation/maintenance phase 1. 18-65 years old, no gender limit; 2. Meet the DSM-5 diagnostic criteria for depression; 3. Currently in the consolidation/maintenance phase, with stable condition, HAMD-17 <7 points; 4. Patients and their guardians understand the nature of this study and sign an informed consent form. 5. Have sufficient audiovisual level to complete the necessary inspections for research; 6. Han nationality 7. Willing to participate in this research; 8. Education level is junior high school and above. 2. Patients with depression in acute onset: 1. 18-65 years old, no gender limit; 2. Meet the DSM-5 diagnostic criteria for depression; 3. Currently in depressive episode, HAMD-17>17 points; 4. Patients and their guardians understand the nature of this study and sign an informed consent form. 5. Have sufficient audiovisual level to complete the necessary inspections for research; 6. Han nationality 7. Willing to participate in this research; 8. Education level is junior high school and above. 3. Healthy control subjects 1. 18-65 years old, no gender limit; 2. Depressive symptoms have never occurred, and it does not meet the DSM-5 diagnostic criteria for depression or other mental disorders; 3. No history of taking psychiatric drugs; 4. Have sufficient audiovisual level to complete the necessary inspections for research; 5. Willing to participate in this research; 6. Education level is junior high school and above. Exclusion Criteria: 1. Patients with depression in the consolidation/maintenance phase 1. Patients with severe brain diseases and other severe physical diseases; 2. Diagnosis of other mental diseases such as schizophrenia and bipolar disorder; 3. There are negative beliefs or a higher risk of suicide; 4. People who are addicted to psychoactive substances such as alcohol or drugs; 5. Women who are pregnant or about to become pregnant recently, and women who are breastfeeding; 6. There are metal implants in the body: there is a pacemaker, intracranial silver clip, metal denture, arterial stent, arterial clip, joint metal fixation, or other metal implant conditions, or non-right-handed (this standard (Only for MRI testers); 7. Failure to sign or refuse to sign the informed consent form. 2. Patients with depression in acute onset: 1. Patients with severe brain diseases and other severe physical diseases; 2. Diagnosis of other mental diseases such as schizophrenia and bipolar disorder; 3. There are negative beliefs or a higher risk of suicide; 4. People who are addicted to psychoactive substances such as alcohol or drugs; 5. Women who are pregnant or about to become pregnant recently, and women who are breastfeeding; 6. There are metal implants in the body: there is a pacemaker, intracranial silver clip, metal denture, arterial stent, arterial clip, joint metal fixation, or other metal implant conditions, or non-right-handed (this standard (Only for MRI testers); 7. Failure to sign or refuse to sign the informed consent form. 3. Healthy control subjects: 1. Two lines and three generations of mental illness history; 2. There are negative beliefs or a higher risk of suicide; 3. Serious brain diseases and other severe physical diseases; 4. Pregnant and lactating women; 5. History of exposure to psychoactive substances such as alcohol or drugs; 6. Failure to sign or refuse to sign the informed consent form. 7. There is a metal implant in the body: there is a pacemaker, intracranial silver clip, metal denture, arterial stent, arterial clip, joint metal fixation, or other metal implant conditions, etc. (this standard is limited to MRI testers ). |
Country | Name | City | State |
---|---|---|---|
China | Shanghai Mental Health Center | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai Mental Health Center |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acoustic parameters | Acoustic parameters of depression patients and healthy subjects are extracted through voice recording. | 2022.6 | |
Primary | Neural activity parameters of EEG | Neural activity parameters of depression patients and healthy subjects are extracted through EEG technology. | 2022.6 | |
Primary | Neural activity parameters of MRI | Neural activity parameters of depression patients and healthy subjects are extracted through MRI. | 2022.6 | |
Primary | Neural activity parameters of near-infrared brain imaging | Neural activity parameters of depression patients and healthy subjects are extracted through near-infrared brain imaging. | 2022.6 | |
Primary | Facial action parameters of facial expression recognition technology | The facial expression recognition technology is implemented by convolutional neural network to extract facial action parameters. | 2022.6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01316926 -
Paxil CR Bioequivalence Study Brazil
|
Phase 1 | |
Recruiting |
NCT06187454 -
Transcranial Direct Current Stimulation for Depression
|
N/A | |
Completed |
NCT04469322 -
Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression
|
N/A | |
Recruiting |
NCT05768126 -
Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine
|
Phase 4 | |
Completed |
NCT03219879 -
Telephone-administered Relapse Prevention for Depression
|
N/A | |
Recruiting |
NCT06038721 -
Unified Protocol: Community Connections
|
N/A | |
Completed |
NCT03043560 -
Study to Treat Major Depressive Disorder With a New Medication
|
Phase 2 | |
Completed |
NCT04091139 -
Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong
|
Phase 2/Phase 3 | |
Completed |
NCT00069459 -
Seasonal Affective Depression (SAD) Study
|
Phase 1 | |
Recruiting |
NCT05503966 -
Combining Antidepressants and Attention Bias Modification in Depression
|
N/A | |
Recruiting |
NCT03001245 -
Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents
|
N/A | |
Completed |
NCT02939560 -
TMS for Adults With Autism and Depression
|
N/A | |
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02542891 -
European Comparative Effectiveness Research on Internet-based Depression Treatment
|
N/A | |
Withdrawn |
NCT02238730 -
Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy
|
N/A | |
Completed |
NCT02224508 -
Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks
|
N/A | |
Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
Completed |
NCT01407575 -
Buprenorphine for Treatment Resistant Depression
|
Phase 3 | |
Completed |
NCT01597661 -
Bupropion & Cardio Birth Defect (Slone)
|
N/A | |
Completed |
NCT01093053 -
Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations
|
N/A |